NetworkNewsBreaks – Genprex, Inc.’s (NASDAQ: G
Post# of 231
(Total Views: 209)
Posted On: 08/06/2019 4:08:38 PM
NetworkNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Manufacturing Partner Aldevron Completes Significant Manufacturing Step for Initial Product Candidate, Oncoprex(TM)
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA per the manufacturing agreement between the companies that was disclosed in September 2018. According to the update, Genprex’s Oncoprex(TM), the company’s initial product candidate, consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a nanovesicle made from lipid molecules with a positive electrical charge. Historically, manufacturing steps have been done for Genprex at MD Anderson Cancer Center, but, since Genprex’s IPO, the company has been working to transfer and scale up these processes through other contract manufacturers. “Each successful release of plasmid DNA batches is an important milestone for Genprex as it allows us to not only demonstrate continued progress in coordinating scale-up manufacturing of Oncoprex, but it takes us one step closer to re-entering the clinic with both our EGFR program and our immunotherapy combination programs,” Genprex President and Chief Operating Officer Julien Pham, MD, said in the news release. “Biologics manufacturing, especially for lipid nanoparticle (or ‘LNP’) delivered gene therapy, is a complex process, but one we tackle with pride alongside dedicated partners such as Aldevron, through a similar vision to deliver innovative therapies to patients with significant unmet medical needs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA per the manufacturing agreement between the companies that was disclosed in September 2018. According to the update, Genprex’s Oncoprex(TM), the company’s initial product candidate, consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a nanovesicle made from lipid molecules with a positive electrical charge. Historically, manufacturing steps have been done for Genprex at MD Anderson Cancer Center, but, since Genprex’s IPO, the company has been working to transfer and scale up these processes through other contract manufacturers. “Each successful release of plasmid DNA batches is an important milestone for Genprex as it allows us to not only demonstrate continued progress in coordinating scale-up manufacturing of Oncoprex, but it takes us one step closer to re-entering the clinic with both our EGFR program and our immunotherapy combination programs,” Genprex President and Chief Operating Officer Julien Pham, MD, said in the news release. “Biologics manufacturing, especially for lipid nanoparticle (or ‘LNP’) delivered gene therapy, is a complex process, but one we tackle with pride alongside dedicated partners such as Aldevron, through a similar vision to deliver innovative therapies to patients with significant unmet medical needs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)